EP1620185A2 - Kosmetische oder pharmazeutische zusammensetzung enthaltend säureamide und deren dermatologische verwendung - Google Patents
Kosmetische oder pharmazeutische zusammensetzung enthaltend säureamide und deren dermatologische verwendungInfo
- Publication number
- EP1620185A2 EP1620185A2 EP04742373A EP04742373A EP1620185A2 EP 1620185 A2 EP1620185 A2 EP 1620185A2 EP 04742373 A EP04742373 A EP 04742373A EP 04742373 A EP04742373 A EP 04742373A EP 1620185 A2 EP1620185 A2 EP 1620185A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- active agent
- composition
- cosmetic
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 title claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 claims abstract description 81
- 239000013543 active substance Substances 0.000 claims abstract description 37
- 229940024606 amino acid Drugs 0.000 claims abstract description 34
- 229960000310 isoleucine Drugs 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 13
- -1 isoleucine amino acid Chemical class 0.000 claims abstract description 5
- 241000196324 Embryophyta Species 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 11
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 10
- 230000016571 aggressive behavior Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 206010001488 Aggression Diseases 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 150000002519 isoleucine derivatives Chemical class 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 210000004400 mucous membrane Anatomy 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 241001312519 Trigonella Species 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000002085 irritant Substances 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 235000012216 bentonite Nutrition 0.000 claims description 2
- 239000003581 cosmetic carrier Substances 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 231100000021 irritant Toxicity 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical compound C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 claims 1
- 206010040914 Skin reaction Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 231100000430 skin reaction Toxicity 0.000 claims 1
- 230000035483 skin reaction Effects 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 45
- OSCCDBFHNMXNME-YUPRTTJUSA-N (4S)-4-hydroxy-L-isoleucine zwitterion Chemical compound C[C@H](O)[C@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-YUPRTTJUSA-N 0.000 description 17
- 238000000605 extraction Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000006205 Balanites Nutrition 0.000 description 1
- 241000935123 Balanites Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241001534110 Lactarius <percoid fish> Species 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000934939 Quararibea Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003124 immunolabeling method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- Cosmetic or pharmaceutical composition comprising amino acids, uses and methods of treatment.
- the invention relates to the field of cosmetics and pharmaceuticals, in particular the field of dermatology.
- the subject of the present invention is the use of at least one isoleucine amino acid, mono or polyhydroxylated, and / or one of these derivatives, as active agent, alone or in combination with at least one other active agent , in or for the preparation of a cosmetic or dermo-pharmaceutical or dermatological composition.
- the skin is a covering organ covering the entire surface of the body. It is a vital organ ensuring multiple functions such as sensory functions, protective vis-à-vis multiple external aggressions, immune, metabolic or thermoregulatory. These roles are made possible thanks to a complex structure which combines various tissue structures.
- the skin, as well as the integuments, are constantly subjected to nuisances of external origin which manifest themselves in different aspects. These attacks can be significant and they can threaten their balance and appearance.
- the search for means in order to preserve the skin and the integuments, or even to protect them against all manifestations liable to affect their proper functioning or their appearance, such as aging, mobilizes a very large number of researchers, in particular in the field of cosmetics .
- the inventors have succeeded in selecting particular substances having remarkable properties when these are applied to the skin.
- the inventors of the present invention have unexpectedly and surprisingly found that particular amino acids exhibit specific biological activities which make them directly usable in cosmetic, dermatological or pharmaceutical preparations or compositions.
- isoleucine and / or its derivatives, mono or polyhydroxylated, in the pharmaceutical field is known in particular for its effective action in the treatment of non-insulin dependent diabetes as described in patent EP 0 587 476.
- the active agent can be defined as being a molecule or a set of molecules capable of bringing modifications or modulations to the functioning of a biological system.
- the amino acid is 4-hydroxyisoleucine of formula:
- the compounds according to the invention relate to the isoleucine derivatives and to the 4-hydroxyisoleucine derivatives.
- isoleucine derivatives is meant both these chemical derivatives and these biological derivatives.
- derivative is meant all the amino acid derivatives leucine or isoleucine to which a group would have been added. This group being capable of bringing better properties to the active agent defined according to the invention.
- the groups can be added in order to facilitate better penetration into the skin, these derivatives being for example radicals of the "oleyl”, “stearyl”, “palmityl” type, etc.
- the amino acid is modified on its carboxylic acid functions and / or on its amino functions.
- the amino acids according to the invention can be modified by acylation or acetylation on their amino function, and / or they can be modified by amidation or esterification on their carboxylic function.
- amino acids may be in the form of lactone.
- amino acids according to the present invention can be found in any existing isometric form.
- 4-hydroxyisoleucine will preferably be used in the form of its isomers (2S, 3R, 4S) and / or (2R, 3R, 4S). These particular isomers being the isomers which are mainly obtained from the process for obtaining 4-hydroxyisoleucine used to obtain the active agent according to the invention. More particularly according to the invention, 4-hydroxyisoleucine is in the form of the (2S, 3R, 4S) isomer.
- the active agent is of plant origin.
- the active principle according to the invention is obtained from plants belonging to the genus Trigonella.
- the amino acid can be obtained from at least any one of the numerous varieties and species belonging to the genus Trigonella.
- the active substance is obtained from at least one plant of the species Trigonella foenum graecum, commonly called fenugreek.
- Fenugreek is an annual herb, it belongs to the sub-order of legumes, to the family of Papilionaceae and to the genus Trigonella. It is a plant cultivated mainly in the Mediterranean regions and known since antiquity for its therapeutic virtues. This plant has the distinction of having a high content of protein material in the seed and especially of having a particular free amino acid, hydroxisoleucine. This amino acid was first identified in 1973 by Fowden et al., It represents more than 60% of the free amino acids present in the seed. Hydroxyisoleucine is also present but in smaller quantities in the leaves and stems of fenugreek. Thus, according to a preferred embodiment of the invention, the active principles will be extracted from the seeds of plants of the genus Trigonella, and more particularly from seeds of the plant of the species Trigonella foenum graecum.
- 4-hydroxyisoleucine is also present in some other plant species; thus Raffholz et al. (1984) have shown the presence of this particular amino acid in Quararibea funebris, a tree in the Bombacaceae family.
- the presence of 4-hydroxyisoleucine has also been reported in species such as Lactarius camphoraius (Dardenne et al., 1986), Dioscoreae delto ⁇ dea and Balanites aegyplia (Hardman and Abu-Al-Futuh, 1976). It is understood that the active compound according to the invention, in particular 4-hydroxyisoleucine, can be obtained from any of the plant species containing it.
- amino acids which are the subject of this patent can be obtained either by conventional chemical synthesis or by extraction or purification from a substance of natural or synthetic origin.
- the active principle is obtained by extraction and / or purification from a natural raw material, in particular vegetable.
- a first step it is possible to grind the seeds, using a plant grinder for example. Then the fenugreek seeds are "defatted” by extraction of fatty substances with conventional organic solvents for this use such as, for example, hexane, chloroform, an alcohol or acetone. According to a variant of the process of the invention, it is possible to use seeds during germination, or even to use only part of the seed containing the embryo and / or the cotyledons.
- the actual extraction is carried out with stirring, at a temperature between 4 and 100 ° C, in an aqueous solution, that is to say composed of water, or by a solution comprising a mixture of water and d 'An organic solvent miscible with water, preferably an alcohol (methanol, ethanol or isopropanol).
- aqueous solution that is to say composed of water
- d 'An organic solvent miscible with water preferably an alcohol (methanol, ethanol or isopropanol).
- the proportion of water in the mixture can vary between 10 and 100%.
- the extraction is carried out at a pH between 2 and 12. According to a variant of the extraction process, this can be made in a mixture of water and polyol; that is to say propylene, dipropylene, butylene or hexylene glycol, or also glycerol.
- the extraction can be carried out using a hydroalcoholic mixture, preferably in a mixture containing approximately 70% of ethanol.
- the alcoholic extract being a first usable form of the extract containing the active agent.
- An alcohol evaporation step can easily be envisaged.
- the soluble fraction is subsequently recovered by centrifugation and by filtration.
- Low molecular weight components, i.e. free amino acids, are separated by dialysis from other higher molecular weight compounds.
- This treatment can consist of bringing our solution into contact with various absorbents such as activated carbon, bleaching earth or silica; then, thereafter, to carry out a filtration step.
- the extract obtained can be further purified by fractionation, in particular by a conventional method of chromatography on ion exchange resin, such as for example by the technique of Moore, Syein and Spackman (1958).
- the extract can also be purified and concentrated by a dialysis process. Any one of the more or less purified forms of the extract is then dissolved in water or in any mixture containing water, then sterilized by ultrafiltration. It is thus possible to easily obtain an extract containing 4-hydroxyisoleucine at a very high degree of purity.
- the invention further relates to the use of at least one amino acid isoleucine and / or an isoleucine derivative, mono or polyhydroxylated, as defined above, in or for the preparation of a composition ; the active agent or the composition being intended to treat in a curative and / or preventive manner the cutaneous manifestations of aging, and / or to improve the appearance of the skin and / or integuments. More generally, the active compound according to the invention will have an effective activity in all skin care and / or integuments. By the care of the skin and / or appendages, is meant all the actions intended to preserve or restore a good functioning of the skin and / or appendages or still any means which is used to preserve or improve their appearance and / or their appearance.
- the treatment includes hydration, soothing, protection against all types of aggression, in particular sun protection, the fight and the prevention of the manifestations of aging, in particular the cutaneous manifestations of aging.
- the expression “cutaneous manifestations of aging” means any modification of the external appearance of the skin due to aging, such as, for example, wrinkles and fine lines, withered skin, soft skin, thinned skin, lack of elasticity and / or skin tone, dull and dull skin but also all internal skin modifications which do not systematically result in a modified external appearance such as, for example, all internal degradations of the skin following exposure to ultraviolet radiation.
- improving the appearance of the skin is meant all the phenomena which are likely to result in a visual improvement in the condition of the skin. The skin will look better; it will, for example, be much more beautiful, firm and / or smooth. All small imperfections will be diminished or removed. The papery appearance of the skin will, for example, be reduced.
- the active agent according to the invention has a particularly effective action on the metabolism of skin cells.
- the active ingredient according to the invention makes it possible in particular to increase the synthesis of proteins essential to its functioning, very particularly by increasing the synthesis of proteins constituting the extracellular matrix.
- proteins constituting the extracellular matrix and particularly effective in the proper functioning of the skin, mention may be made of laminin, fibronectin, elastin or even collagen.
- laminin, fibronectin, elastin or even collagen As proteins constituting the extracellular matrix, and particularly effective in the proper functioning of the skin, mention may be made of laminin, fibronectin, elastin or even collagen.
- the increased expression of these proteins has been demonstrated by numerous tests using immunolabeling methods.
- the active agent according to the invention, or the composition containing it has a truly positive action on the tissue regeneration of the skin as well as on scarring.
- the active agent according to the invention has beneficial effects in terms of protein synthesis of keratinocytes.
- Another subject of the invention therefore is the use of at least one active ingredient as defined above, or of a cosmetic composition comprising it, in order to increase the synthesis of keratins.
- This active ingredient in particular promotes cell differentiation of keratinocytes, the latter therefore migrate more rapidly towards the surface of the epidermis and ensure better resistance of the stratum corneum. While progressing towards the higher layers, the keratinocytes flatten and pour into the extracellular space a cement made up of lipids, cholesterol, free saturated fatty acids and ceramides which increase the cohesion between cells and thus contribute to the barrier role of the epidemic.
- the active ingredient according to the invention therefore has an effective action on the skin barrier, this active ingredient therefore increases this barrier function.
- the active principle or the composition according to the invention can be intended to protect keratinous substrates, and more particularly to protect the skin and / or the integuments against all types of external aggressions.
- This active agent, or of a composition containing it will allow the keratinous substrates to be protected and to better resist the stress that the environment produces on them.
- the term "external aggression” means the aggressions that the environment can produce. These attacks can be of chemical, physical, biological or thermal origin. By way of example, mention may be made of aggressions such as pollution, UV, friction, water with a high concentration of limestone, temperature variations or even products with an irritant nature such as surfactants, preservatives or the perfumes.
- the active agent, or the composition containing it has anti-inflammatory and anti-irritant effects. The use of the properties of this cosmetic agent therefore makes it possible to have a more protected skin and clearly less sensitive to the various aggressions it may encounter. The skin is soothed.
- the subject of the invention is a cosmetic and / or dermatological and / or dermo-pharmaceutical composition containing, as active ingredient, in a cosmetically or pharmaceutically acceptable medium, at least one compound as defined above; that is to say an amino acid isoleucine, mono or polyhydroxylated, and / or one of its derivatives.
- the amino acid of the composition is 4-hydroxyisoleucine.
- the active substance is obtained from at least one plant of the species Trigonella foenum graecum.
- the part used for the preparation of the active agent is the plant seed.
- the composition according to the invention may be a cosmetic and / or dermatological and / or dermo-pharmaceutical composition.
- the composition is a cosmetic composition, because it is intended to improve the appearance and the general cutaneous performance of the individual who uses it.
- the composition according to the invention is preferably a composition suitable for administration by the route external topical, mainly on the skin, mucous membranes and / or integuments, comprising a cosmetically or dermatologically acceptable medium.
- the invention is intended for mammals in general and more particularly for human beings.
- the effective amount of active ingredient corresponds to the amount necessary to obtain the desired result.
- the abovementioned active principle is present, in the compositions of the invention, at a concentration of between 0.00001% and 20% approximately, and preferably at a concentration of between 0.001 % and approximately 10% by weight relative to the total weight of the final composition.
- the abovementioned active agent is dissolved beforehand in one or more cosmetically or pharmaceutically acceptable solvents such as water, ethanol, propanol or isopropanol, propylene glycol, butylene glycol, dipropylene glycol, ethoxylated or propoxylated diglycols or any mixture of these solvents.
- one or more cosmetically or pharmaceutically acceptable solvents such as water, ethanol, propanol or isopropanol, propylene glycol, butylene glycol, dipropylene glycol, ethoxylated or propoxylated diglycols or any mixture of these solvents.
- the abovementioned active agent is dissolved beforehand in a cosmetic or pharmaceutical carrier such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally solubilized in or attached to any cosmetically or pharmaceutically acceptable carrier.
- a cosmetic or pharmaceutical carrier such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally solubilized in or attached to any cosmetically or pharmaceutically acceptable carrier.
- the composition according to the invention can be ingested, injected or applied to the skin (on any cutaneous zone of the body), the hair, the nails or the mucous membranes.
- the composition according to the invention can be in all the galenical forms normally used.
- the compositions according to the present invention will be in a dosage form suitable for administration by the topical skin route. They cover all cosmetic and dermatological forms. These compositions must therefore contain a cosmetically acceptable medium, that is to say compatible with the skin, hair or hair.
- compositions can in particular be in the form of an aqueous, hydroalcoholic or oily solution; an oil-in-water, water-in-oil or multiple emulsion; they can also be in the form of creams, suspensions or even powders, suitable for application to the skin, mucous membranes, lips and / or the hair.
- These compositions can be more or less fluid and have the appearance of a cream, a lotion, a milk, a serum, an ointment, a shampoo, a gel, a paste or foam. They can also be in solid form, such as a stick or be applied to the skin in the form of an aerosol. They can be used as a care product and / or as a make-up product for the skin.
- the composition according to the invention can be in the form of an aqueous, oily lotion or in the form of serum.
- the composition can be in the form of drops and for ingestion, it can be in the form of capsules, granules, syrups or tablets.
- These compositions also include any additive commonly used in the intended field of application as well as the adjuvants necessary for their formulation, such as solvents, thickeners, diluents, antioxidants, dyes, sunscreens, self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, cosmetic or pharmaceutical active ingredients, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc. .
- these adjuvants are chosen so as not to harm the desired advantageous properties of the composition according to the invention.
- These adjuvants can, for example, correspond from 0.01 to 20% of the total weight of the composition.
- the fatty phase can represent from 5 to 80% by weight and preferably from 5 to 50% by weight relative to the total weight of the composition.
- the emulsifiers and co-emulsifiers used in the composition will be chosen from those conventionally used in the field under consideration. For example, they can be used in a proportion ranging from 0.3 to 30% by weight, relative to the total weight of the composition.
- those skilled in the art will take care to choose any additional compounds, active or non-active, and / or their quantities, so that the advantageous properties of the mixture are not, or not substantially, altered by the addition considered.
- compositions according to the invention find application in particular as a cosmetic or pharmaceutical composition for the skin, mucous membranes and / or semi-mucous membranes, but also as a cosmetic composition for the hair and / or body hair. They find a very particular application as a product for protecting and / or caring for the skin.
- compositions which are the subject of the invention find their application in a large number of treatments, in particular cosmetic or dermatological treatments, and they can constitute a cosmetic composition, in particular for the treatment, protection, care, make-up removal and / or cleaning of the skin, lips and / or hair, and / or for making up the skin, lips, eyelashes and / or body.
- the composition according to the invention may also consist of solid preparations also comprising soaps or cleaning bars.
- the composition can also be packaged in the form of an aerosol composition also comprising a propellant under pressure.
- the composition can also be for oral use, such as for example a toothpaste paste.
- the composition of the invention can also be a cosmetic composition intended for oral administration.
- the composition according to the invention can be in any suitable form, particularly in the form of an oral solution, a syrup, a tablet, a dragee, a capsule or still a food or nutritional supplement.
- the present invention relates to a cosmetic treatment method for caring for the skin and / or integuments comprising applying to the surface of the skin an effective amount of active agent as defined above, in order to obtain the desired action.
- These methods can in particular be used in order to preventively and / or curatively treat the manifestations of skin aging, but also in order to protect the skin and / or the integuments against external aggressions, or also in order to combat the manifestations of the skin inflammation and irritation.
- Particular embodiments of this cosmetic treatment process also result from the preceding description.
- the cosmetic treatment method of the invention can be implemented in particular by applying the cosmetic compositions as defined above, according to the usual technique for using these compositions, for example: application of creams, gels, serums , lotions, milks, shampoos or sunscreen compositions, on the skin or on the hair, or else application of toothpaste on the gums.
- application of creams, gels, serums , lotions, milks, shampoos or sunscreen compositions for example: application of creams, gels, serums , lotions, milks, shampoos or sunscreen compositions, on the skin or on the hair, or else application of toothpaste on the gums.
- Example 1 Preparation of 4-hydroxyisoleucine. A quantity of 100 grams of defatted seeds of the plant of the species Trigonella foenum graecum is ground in a knife mill, at a particle size of 200mm.
- the concentrate is passed through a column containing a cation exchange resin so as to retain the amino acid 4-hydroxyisoleucine, which is then eluted using, for example, an ammonia solution.
- the solution thus obtained is concentrated in 70% ethanol, then a new purification step is carried out by passing the mixture over an adsorption chromatography on silica gel.
- the column is eluted with 70% ethanol.
- the recovered mixture is concentrated so as to obtain a solution containing an optimal level of 4-hydroxyisoleucine.
- phase A and phase B are heated separately to a temperature between 65 ° C and 70 ° C, phase C is incorporated, then phase A is emulsified in phase B.
- the Carbomer is neutralized with the phase D at a temperature around 45 ° C.
- Phase E is then added with stirring and the cooling is continued to 25 ° C.
- phase A and phase B are heated separately to a temperature between 70 ° C and 75 ° C.
- Phase B is emulsified in A with “Staro” stirring. After cooling to 50 ° C, the mixture is neutralized with phase C.
- Phase D is then added when the temperature is below 40 ° C. Cooling is continued to 25 ° C with slow stirring.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0303886A FR2852841B1 (fr) | 2003-03-28 | 2003-03-28 | Composition cosmetique ou pharmaceutique comprenant des acides amines, utilisations et procedes de traitement |
| PCT/FR2004/000769 WO2004087091A2 (fr) | 2003-03-28 | 2004-03-26 | Composition cosmetique ou pharmaceutique comprenant des acides amines, utilisation et procede de traitement dermatologique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1620185A2 true EP1620185A2 (de) | 2006-02-01 |
Family
ID=32947268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04742373A Withdrawn EP1620185A2 (de) | 2003-03-28 | 2004-03-26 | Kosmetische oder pharmazeutische zusammensetzung enthaltend säureamide und deren dermatologische verwendung |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1620185A2 (de) |
| FR (1) | FR2852841B1 (de) |
| WO (1) | WO2004087091A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2887773B1 (fr) * | 2005-07-01 | 2008-05-30 | Soc Extraction Principes Actif | Utilisation d'un acide amine en tant qu'agent actif inducteur de la synthese des proteines sirt dans les cellules de la peau. |
| WO2008102671A1 (ja) | 2007-02-22 | 2008-08-28 | Ajinomoto Co., Inc. | 4-ヒドロキシイソロイシンの精製方法 |
| CN104027266A (zh) * | 2014-05-26 | 2014-09-10 | 邓林生 | 高效生发乳液的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2695317B1 (fr) * | 1992-09-07 | 1995-03-10 | Monal Lab | Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant. |
| IL108583A (en) * | 1994-02-07 | 1997-06-10 | Yissum Res Dev Co | Galactomannan emulsions and comestible products containing the same |
-
2003
- 2003-03-28 FR FR0303886A patent/FR2852841B1/fr not_active Expired - Fee Related
-
2004
- 2004-03-26 EP EP04742373A patent/EP1620185A2/de not_active Withdrawn
- 2004-03-26 WO PCT/FR2004/000769 patent/WO2004087091A2/fr not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2004087091A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2852841A1 (fr) | 2004-10-01 |
| WO2004087091A3 (fr) | 2004-11-11 |
| FR2852841B1 (fr) | 2006-08-04 |
| WO2004087091A2 (fr) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2408670A1 (fr) | Nouveaux composes de la famille des n-acylamino-amides, compositions les comprenant, et utilisations | |
| EP1001740B1 (de) | Verwendung von ginsenoside rb1 zur stimulierung der elastinsynthese | |
| FR3110417A1 (fr) | Absolues pour leur utilisation cosmétique | |
| FR2837098A1 (fr) | Composition cosmetique ou pharmaceutique comprenant des peptides, procedes de traitement et utilisations | |
| EP0973494B1 (de) | Verwendung eines adansonia-gattung extraktes | |
| FR2918893A1 (fr) | Utilisation d'un principe actif issu du lin pour preparer une composition destinee a activer le cytochrome c | |
| CA2407294A1 (fr) | Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations | |
| CA2391588A1 (fr) | Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un compose anti-inflammatoire | |
| WO1999063963A1 (fr) | Compositions a usage cosmetique ou dermopharmaceutique contenant un melange d'extraits de cafe vert et de beurre de karite | |
| FR3016289A1 (fr) | Extrait vegetal comprenant des sucrose-esters en tant que principe actif et son utilisation dans une composition cosmetique, dermatologique ou nutraceutique | |
| EP3579929B1 (de) | Marsdenia cundurango | |
| EP1530480B1 (de) | Kosmetische zusammensetzung mit monosacchariden oder polysacchariden, anwendungen und behandlungsverfahren | |
| FR2865652A1 (fr) | Utilisation d'extraits de plantes et de molecules purifiees pour des compositions cosmetique, nutraceutique ou pharmaceutique a action amincissante lipolytique. | |
| FR2722100A1 (fr) | Extrait de graine de pervenche et composition le contenant | |
| EP0602029B1 (de) | Kosmetisches oder pharmazeutisches mittel, das ein coleus esquirolii, coleus scutellarioides oder coleus xanthanthusextrakt enthält | |
| WO2004087091A2 (fr) | Composition cosmetique ou pharmaceutique comprenant des acides amines, utilisation et procede de traitement dermatologique | |
| EP1569614B1 (de) | Verwendung eines im extrakt einer baumwolle enthaltenen honigtaus als wirkstoff | |
| WO2019077268A1 (fr) | Composition cosmétique de prévention active des signes de l'âge | |
| FR3143372A1 (fr) | Composition neurocosmetique pour prevenir les effets du stress | |
| FR2759910A1 (fr) | Compositions cosmetiques ou dermopharmaceutiques pour le raffermissement du buste, la stimulation du systeme capillaire et l'inhibition ou systeme pileux, contenant des extraits de kigelia africana | |
| WO1994015626A9 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de vismia | |
| EP0493223B1 (de) | Kosmetische Zusammensetzung auf der Basis von Pflanzenextrakten | |
| FR3110426A1 (fr) | Nouvel extrait de roses pour son utilisation cosmétique | |
| WO2004030645A1 (fr) | Utilisation d'un extrait de marc de poire comme principe actif dans une composition cosmetique et/ou pharmaceutique | |
| FR2899105A1 (fr) | Composition cosmetique et/ou pharmaceutique comprenant comme ingredient actif, au moins un hydrolysat de proteines de poacees et utilisation de cet hydrolysat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20051017 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20070823 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20091001 |